Incidence and dosimetric predictive factors of late rectal toxicity after low-dose-rate brachytherapy combined with volumetric modulated arc therapy in high-risk prostate cancer at a single institution: Retrospective study.

[1]  M. Matsuo,et al.  Predictive factors of rectal hemorrhage in patients with localized prostate cancer who underwent low-dose-rate brachytherapy , 2020, International Journal of Clinical Oncology.

[2]  Tomoki Tanaka,et al.  Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients. , 2018, Brachytherapy.

[3]  G. Cohen,et al.  Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103. , 2017, Brachytherapy.

[4]  J. Benlloch,et al.  High-dose-rate brachytherapy boost for prostate cancer: Analysis of dose-volume histogram parameters for predicting late rectal toxicity. , 2017, Brachytherapy.

[5]  W. Brannath,et al.  Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use? , 2017, The British journal of radiology.

[6]  J. Dai,et al.  Dosimetric comparison of intensity‐modulated radiotherapy and volumetric‐modulated arc radiotherapy in patients with prostate cancer: a meta‐analysis , 2016, Journal of applied clinical medical physics.

[7]  N. Katayama,et al.  Predictive factors of rectal toxicity after permanent iodine-125 seed implantation: Prospective cohort study in 2339 patients. , 2016, Brachytherapy.

[8]  M. Hagan,et al.  Comparative study of late rectal toxicity in prostate cancer patients treated with low-dose-rate brachytherapy: With or without supplemental external beam radiotherapy. , 2016, Brachytherapy.

[9]  M. Cooperberg,et al.  Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. , 2015, European urology.

[10]  N. Katayama,et al.  Urinary and Rectal Toxicity Profiles After Permanent Iodine-125 Implant Brachytherapy in Japanese Men: Nationwide J-POPS Multi-institutional Prospective Cohort Study. , 2015, International journal of radiation oncology, biology, physics.

[11]  K. Wallner,et al.  Severe rectal complications after prostate brachytherapy. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  R. Stock,et al.  Clinical Investigation : Genitourinary Cancer Predictive Factors and Management of Rectal Bleeding Side Effects Following Prostate Cancer Brachytherapy , 2022 .

[13]  P. Hoskin,et al.  GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  H. Ariga,et al.  Three-dimensional summation of rectal doses in brachytherapy combined with external beam radiotherapy for prostate cancer. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[15]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[16]  Issam El Naqa,et al.  Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. , 2012, International journal of radiation oncology, biology, physics.

[17]  R. Stock,et al.  Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer. , 2012, International journal of radiation oncology, biology, physics.

[18]  Hiroyuki Takahashi,et al.  Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): study protocol for a phase III, multicenter, randomized, controlled trial , 2012, BMC Cancer.

[19]  M. Duff,et al.  VMAT vs. 7-field-IMRT: assessing the dosimetric parameters of prostate cancer treatment with a 292-patient sample. , 2011, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[20]  N. Shigematsu,et al.  Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients. , 2011, International journal of radiation oncology, biology, physics.

[21]  Martin Carolan,et al.  Comparison of prostate IMRT and VMAT biologically optimised treatment plans. , 2011, Medical dosimetry : official journal of the American Association of Medical Dosimetrists.

[22]  Barry S Rosenstein,et al.  Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. , 2005, International journal of radiation oncology, biology, physics.

[23]  R K Ten Haken,et al.  The effect of patient position and treatment technique in conformal treatment of prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[24]  W. Butler,et al.  Rectal dosimetric analysis following prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[25]  R. Stock,et al.  A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. , 1995, International journal of radiation oncology, biology, physics.

[26]  R G Dale,et al.  The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. , 1985, The British journal of radiology.

[27]  J. Blasko,et al.  American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. , 2017, Brachytherapy.

[28]  B. Kragelj,et al.  Avoidance of late rectal toxicity after high-dose-rate brachytherapy boost treatment for prostate cancer. , 2017, Brachytherapy.

[29]  Marco Zaider,et al.  Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy. , 2008, Brachytherapy.

[30]  G J Kutcher,et al.  The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with three-dimensional conformal radiotherapy. , 1997, International journal of radiation oncology, biology, physics.